Replies to post #445454 on ORIONS Money Stocks

[maent]

Kitov Announces U.S. Commercial Launch of Consensi(TM)



Kitov Announces U.S. Commercial Launch of Consensi(TM)

TEL AVIV, Israel, May 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced the U.S. commercial launch of Consensi(TM), a fixed-dose combination of celecoxib and amlodipine besylate, designed for the simultaneous treatment of hypertension and osteoarthritis pain. Consensi(TM) is being sold in the U.S. by Burke Therapeutics, the marketing partner of Kitov's U.S. distributor, Coeptis Pharmaceuticals.

"Consensi(TM) provides a new therapeutic option for patients suffering from both hypertension and osteoarthritis-related pain. We are excited about the availability of Consensi(TM) for patients", said Dave Mehalick, Chief Executive Officer of Coeptis Pharmaceuticals.

"We are please Consensi(TM) is now available and our sales team is eager to introduce this one tablet, once a day treatment for hypertension and osteoarthritis pain to the U.S. market", said Angela Sutterer, Chief Executive Officer of Burke Therapeutics.

"The initial U.S. sales of Consensi(TM) represents a key milestone for Kitov," said Isaac Israel, Chief Executive Officer of Kitov. "We are confident that Coeptis' and Burke's extensive distribution reach will enable us to maximize Consensi(TM)'s market potential. The projected royalties and milestone revenues from our U.S. marketing and distribution agreements for Consensi(TM), together with the $26 million gross fundraising proceeds we secured this year, will provide the source of financial support for our development efforts aimed at advancing our emerging oncology pipeline, including advancing both NT-219 and CM-24 into significant value creating clinical milestones. We look forward to providing further updates about Consensi(TM)'s marketing activities and progress soon."